AEGiS-PRn: Chemokine Modulators Likely to Generate Blockbuster Sales Through Use in Multiple Disease Drug Markets: HIV Market To Significantly Benefit From Chemokine Receptor Antagonists, According To New Report From Decision Resources

Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.

Chemokine Modulators Likely to Generate Blockbuster Sales Through Use in Multiple Disease Drug Markets: HIV Market To Significantly Benefit From Chemokine Receptor Antagonists, According To New Report From Decision Resources

PRNewswire - November 20, 2002

WALTHAM, Mass., Nov. 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and health care issues, forecast today that chemokine modulators are likely to generate blockbuster sales because of their use in multiple disease drug markets. By far the greatest potential lies in the development of chemokine modulators for the treatment of inflammatory and immune-mediated diseases such as rheumatoid arthritis, asthma, and multiple sclerosis. Within these disease areas, the most important advantage chemokine modulators are likely to offer is their selectivity and specificity in therapy. The HIV drug market is also likely to benefit greatly from chemokine modulators, potentially generating $1-2 billion for this market by 2012, according to a new Pathways and Processes report entitled Chemokine Modulators: Emerging Therapeutic Opportunities.

"Inhibitors of the chemokine receptors CCR5 and CXCR4 are the most promising emerging class of antiretrovirals (ARVs), and are likely to provide the next 'breakthrough' advance in HIV therapy," said John Lebbos, M.D., analyst at Decision Resources, "Schering-Plough, Pfizer, Merck, and Progenics are all competing for first-to-market chemokine modulators for the HIV market."

Chemokines Facts

Chemokines are a family of structurally related glycoproteins that are involved in the recruitment and activation of leukocytes. Chemokines play a central role in several physiological and pathological processes including inflammation, viral infection, and cancer. In an increasingly competitive industry, biopharmaceutical manufacturers are under mounting pressure to market an annual array of blockbuster drugs. In this quest for novel drugs and drug targets, the chemokine system provides vast commercial potential. Future therapeutic opportunities for chemokine modulators are vast and include applications in inflammation, autoimmune diseases, infectious diseases, and cancer.

Decision Resources

Chemokine Modulators: Emerging Therapeutic Applications is the third report from Pathways and Processes, a new advisory service that focuses on cellular and molecular pathways. The reports provide insight into cutting-edge developments relating to drug targets with the potential to significantly change treatment practice and impact multiple pharmaceutical markets.

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

CONTACT:

Elizabeth Marshall, emarshall@dresources.com

Decision Resources, 781-296-2563

SOURCE Decision Resources

Photo Notes: NewsCom:

http://www.newscom.com/cgi-bin/prnh/20000303/DECISION AP Archive:

http://photoarchive.ap.org PRN Photo Desk, 888-776-6555 or 212-782-2840

Web Site: http://www.dresources.com

DECISION RESOURCES Decision Resources, Inc., is a world leader in primary and secondary research publications, multi-client advisory services, and customized consulting. More than 1,000 leading organizations and 100 percent of the 25 largest global pharmaceutical companies turn to Decision Resources for their strategic planning, market development, and competitive intelligence requirements. Founded as a subsidiary of Arthur D. Little, Inc., Decision Resources has provided strategic information services for 30 years. Decision Resources is headquartered in Waltham, Massachusetts, with offices in Brussels, London, and Tokyo. (PRNewsFoto)[AG] WALTHAM, MA USA 03/03/2000

021120
PR021127

Copyright © 2002 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .